Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib Plus Dexamethasone in RRMM
NCT03512353Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jul 2018
- Primary completion
- Jan 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Primary endpoints: Number of Participants Who Completed 12 Cycles of Treatment, Percentage of Expected Dose of Carfilzomib Received and 3 more. Started Jul 2018; status: terminated.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03512353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512353.